June in Review: Updates on the Psychiatric Treatment Pipeline
Psychiatric Times
JUNE 30, 2025
Compass Pathways' COMP360 psilocybin has shown significant efficacy in a phase 3 trial for treatment-resistant depression, advancing psychedelic research in mental health. A recently filed patent on its preservative-free manufacturing process may further support market exclusivity.
Let's personalize your content